Silence Therapeutics completes enrollment in phase 2 PV study
Tweet Send to a Friend
Silence Therapeutics plc (NASDAQ: SLN) completed patient enrollment in its SANRECO Phase 2 study of divesiran for polycythemia vera treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




